QQQ   281.48 (+0.32%)
AAPL   141.57 (+0.28%)
MSFT   241.86 (+0.64%)
META   111.56 (+1.92%)
GOOGL   95.89 (+0.74%)
AMZN   92.11 (-0.34%)
TSLA   182.77 (+1.07%)
NVDA   158.79 (+1.53%)
NIO   12.32 (+17.33%)
BABA   87.15 (+9.13%)
AMD   73.71 (+0.44%)
T   18.96 (-0.26%)
MU   54.74 (-0.69%)
CGC   3.48 (+1.75%)
F   13.57 (-1.31%)
GE   84.32 (-1.56%)
DIS   94.59 (-0.11%)
AMC   7.20 (-3.10%)
PYPL   76.28 (-1.75%)
PFE   49.41 (-0.16%)
NFLX   290.92 (+3.54%)
QQQ   281.48 (+0.32%)
AAPL   141.57 (+0.28%)
MSFT   241.86 (+0.64%)
META   111.56 (+1.92%)
GOOGL   95.89 (+0.74%)
AMZN   92.11 (-0.34%)
TSLA   182.77 (+1.07%)
NVDA   158.79 (+1.53%)
NIO   12.32 (+17.33%)
BABA   87.15 (+9.13%)
AMD   73.71 (+0.44%)
T   18.96 (-0.26%)
MU   54.74 (-0.69%)
CGC   3.48 (+1.75%)
F   13.57 (-1.31%)
GE   84.32 (-1.56%)
DIS   94.59 (-0.11%)
AMC   7.20 (-3.10%)
PYPL   76.28 (-1.75%)
PFE   49.41 (-0.16%)
NFLX   290.92 (+3.54%)
QQQ   281.48 (+0.32%)
AAPL   141.57 (+0.28%)
MSFT   241.86 (+0.64%)
META   111.56 (+1.92%)
GOOGL   95.89 (+0.74%)
AMZN   92.11 (-0.34%)
TSLA   182.77 (+1.07%)
NVDA   158.79 (+1.53%)
NIO   12.32 (+17.33%)
BABA   87.15 (+9.13%)
AMD   73.71 (+0.44%)
T   18.96 (-0.26%)
MU   54.74 (-0.69%)
CGC   3.48 (+1.75%)
F   13.57 (-1.31%)
GE   84.32 (-1.56%)
DIS   94.59 (-0.11%)
AMC   7.20 (-3.10%)
PYPL   76.28 (-1.75%)
PFE   49.41 (-0.16%)
NFLX   290.92 (+3.54%)
QQQ   281.48 (+0.32%)
AAPL   141.57 (+0.28%)
MSFT   241.86 (+0.64%)
META   111.56 (+1.92%)
GOOGL   95.89 (+0.74%)
AMZN   92.11 (-0.34%)
TSLA   182.77 (+1.07%)
NVDA   158.79 (+1.53%)
NIO   12.32 (+17.33%)
BABA   87.15 (+9.13%)
AMD   73.71 (+0.44%)
T   18.96 (-0.26%)
MU   54.74 (-0.69%)
CGC   3.48 (+1.75%)
F   13.57 (-1.31%)
GE   84.32 (-1.56%)
DIS   94.59 (-0.11%)
AMC   7.20 (-3.10%)
PYPL   76.28 (-1.75%)
PFE   49.41 (-0.16%)
NFLX   290.92 (+3.54%)
OTCMKTS:CVSI

CV Sciences - CVSI Stock Forecast, Price & News

$0.03
-0.01 (-14.18%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.03
▼
$0.04
50-Day Range
$0.03
▼
$0.05
52-Week Range
$0.03
▼
$0.27
Volume
598,739 shs
Average Volume
366,836 shs
Market Capitalization
$5.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$0.17

CV Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
401.5% Upside
$0.17 Price Target
Short Interest
Healthy
1.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

See Top Rated MarketRank™ Stocks Here
CVSI stock logo

About CV Sciences (OTCMKTS:CVSI) Stock

CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

Receive CVSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter.

CVSI Stock News Headlines

November 14, 2022 | msn.com
Why Is CV Sciences Stock Up Today?
November 14, 2022 | seekingalpha.com
CV Sciences, Inc. (CVSI) Q3 2022 Earnings Call Transcript
November 14, 2022 | finance.yahoo.com
CV Sciences, Inc. Reports Third Quarter 2022 Financial Results
November 8, 2022 | finance.yahoo.com
CV SCIENCES, INC. TO ANNOUNCE THIRD QUARTER 2022 RESULTS ON NOVEMBER 14, 2022
October 1, 2022 | seekingalpha.com
CVSI CV Sciences, Inc.
August 25, 2022 | finance.yahoo.com
CV Sciences, Inc. Extinguishes Convertible Debt
August 15, 2022 | seekingalpha.com
CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q2 2022 Results - Earnings Call Transcript
August 15, 2022 | finance.yahoo.com
CV Sciences, Inc. Reports Second Quarter 2022 Financial Results
August 15, 2022 | finance.yahoo.com
CV Sciences, Inc. Announces Launch of PlusCBD™ Reserve Collection Softgels
May 16, 2022 | seekingalpha.com
CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q1 2022 Results - Earnings Call Transcript
May 16, 2022 | finance.yahoo.com
CV Sciences, Inc. Reports First Quarter 2022 Financial Results
May 15, 2022 | markets.businessinsider.com
CV Sciences earnings preview: what Wall Street is expecting
May 13, 2022 | seekingalpha.com
CV Sciences Q1 2022 Earnings Preview
May 12, 2022 | finance.yahoo.com
CV Sciences, Inc. to Announce First Quarter 2022 Results On May 16, 2022
March 31, 2022 | finance.yahoo.com
CV Sciences, Inc. Reports Fiscal Year-End 2021 Financial Results
March 28, 2022 | finance.yahoo.com
CV Sciences, Inc. to Announce Fourth Quarter and Full Year 2021 Results on March 31, 2022
March 11, 2022 | finance.yahoo.com
UPDATE -- CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Products
March 8, 2022 | finance.yahoo.com
CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Products
January 11, 2022 | finance.yahoo.com
CV Sciences, Inc. Announces Launch of +PlusCBD™ Pain Relief Topicals
January 11, 2022 | benzinga.com
CV Sciences Launches +PlusCBD Pain Relief Topicals With Products For Athletes, Arthritis Patients
January 6, 2022 | msn.com
Nutrition Giant GNC To Distribute CBD Products In 770 Stores In US
January 5, 2022 | msn.com
Is Medical Marijuana Really A Slippery Slope? CVSI Distribution Agreement with GNC
January 5, 2022 | seekingalpha.com
CV Sciences signs distribution deal with GNC
January 5, 2022 | finance.yahoo.com
CV Sciences, Inc. Announces New Distribution Agreement with GNC
November 30, 2021 | finance.yahoo.com
CV Sciences, Inc. Appoints Haskell & White LLP as Auditor
See More Headlines
Receive CVSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter.

CVSI Company Calendar

Last Earnings
11/14/2022
Today
11/30/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CVSI
Previous Symbol
NASDAQ:CVSI
CUSIP
N/A
CIK
1510964
Web
www.cvsciences.com
Phone
(866) 290-2157
Fax
619-876-4321
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$0.17
High Stock Price Forecast
$0.17
Low Stock Price Forecast
$0.17
Forecasted Upside/Downside
+401.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.14)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-15,550,000.00
Net Margins
-85.28%
Pretax Margin
-85.84%
Return on Equity
-560.71%
Return on Assets
-87.75%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.90
Quick Ratio
0.37

Sales & Book Value

Annual Sales
$20.05 million
Price / Sales
0.25
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.01 per share
Price / Book
3.39

Miscellaneous

Outstanding Shares
150,630,000
Free Float
146,267,000
Market Cap
$5.11 million
Optionable
Not Optionable
Beta
0.87

Key Executives

  • Mr. Joseph D. Dowling (Age 65)
    CEO, Sec. & Director
    Comp: $418.52k
  • Mr. Joerg Grasser (Age 47)
    Chief Financial Officer
    Comp: $251.54k
  • Mr. Tim Hitchman
    VP of Operations
  • Mr. Stuart Tomc
    Sr. VP of Human Nutrition
  • Mr. Jesse Karagianes
    Sr. VP of Revenue Growth
  • Ms. Alyssa Dunn
    Operations Mang.

Key Competitors

View All Competitors













CVSI Stock - Frequently Asked Questions

Should I buy or sell CV Sciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CVSI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVSI, but not buy additional shares or sell existing shares.
View CVSI analyst ratings or view top-rated stocks.

What is CV Sciences' stock price forecast for 2023?

2 analysts have issued twelve-month price targets for CV Sciences' shares. Their CVSI share price forecasts range from $0.17 to $0.17. On average, they anticipate the company's share price to reach $0.17 in the next twelve months. This suggests a possible upside of 401.5% from the stock's current price.
View analysts price targets for CVSI or view top-rated stocks among Wall Street analysts.

How have CVSI shares performed in 2022?

CV Sciences' stock was trading at $0.12 at the beginning of 2022. Since then, CVSI shares have decreased by 71.8% and is now trading at $0.0339.
View the best growth stocks for 2022 here.

How were CV Sciences' earnings last quarter?

CV Sciences, Inc. (OTCMKTS:CVSI) posted its quarterly earnings data on Monday, November, 14th. The company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.02) by $0.01. The business had revenue of $3.75 million for the quarter, compared to analysts' expectations of $4.03 million. CV Sciences had a negative trailing twelve-month return on equity of 560.71% and a negative net margin of 85.28%.

What other stocks do shareholders of CV Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include Aurora Cannabis (ACB), Cronos Group (CRON), Charlotte's Web (CWBHF), KushCo (KSHB), OrganiGram (OGI), GW Pharmaceuticals (GWPH), Tilray (TLRY) and Medical Marijuana (MJNA).

What is CV Sciences' stock symbol?

CV Sciences trades on the OTCMKTS under the ticker symbol "CVSI."

How do I buy shares of CV Sciences?

Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CV Sciences' stock price today?

One share of CVSI stock can currently be purchased for approximately $0.03.

How much money does CV Sciences make?

CV Sciences (OTCMKTS:CVSI) has a market capitalization of $5.11 million and generates $20.05 million in revenue each year. The company earns $-15,550,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

How can I contact CV Sciences?

CV Sciences' mailing address is 10070 BARNES CANYON ROAD, SAN DIEGO CA, 92121. The official website for the company is www.cvsciences.com. The company can be reached via phone at (866) 290-2157, via email at ir@cvsciences.com, or via fax at 619-876-4321.

This page (OTCMKTS:CVSI) was last updated on 11/30/2022 by MarketBeat.com Staff